HC Wainwright Boosts Compass Therapeutics (NASDAQ:CMPX) Price Target to $24.00

Compass Therapeutics (NASDAQ:CMPX - Free Report) had its price target lifted by HC Wainwright from $10.00 to $24.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts have also issued reports on the company. Leerink Partnrs upgraded Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 1st. Piper Sandler initiated coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price objective on the stock. Wedbush reaffirmed an "outperform" rating and set a $8.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, April 1st. Jefferies Financial Group raised their price target on Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Monday, February 10th. Finally, Leerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and lifted their price target for the stock from $4.00 to $6.00 in a report on Wednesday, April 2nd. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $13.38.

Compass Therapeutics Stock Up 10.6 %

NASDAQ CMPX traded up $0.17 during trading on Friday, hitting $1.76. The stock had a trading volume of 7,896,601 shares, compared to its average volume of 849,568. The company has a market capitalization of $243.24 million, a PE ratio of -4.74 and a beta of 1.40. The firm has a 50 day moving average price of $2.67 and a 200 day moving average price of $2.10. Compass Therapeutics has a twelve month low of $0.77 and a twelve month high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). On average, sell-side analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current year.

Insiders Place Their Bets

In other Compass Therapeutics news, insider Jonathan Anderman acquired 20,000 shares of the company's stock in a transaction on Monday, April 7th. The shares were bought at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the purchase, the insider now owns 21,000 shares in the company, valued at $32,340. This trade represents a 2,000.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 28.50% of the company's stock.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors have recently added to or reduced their stakes in CMPX. Intech Investment Management LLC acquired a new stake in Compass Therapeutics during the 3rd quarter worth approximately $30,000. Tower Research Capital LLC TRC lifted its holdings in shares of Compass Therapeutics by 298.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock worth $25,000 after purchasing an additional 12,917 shares during the period. Independent Advisor Alliance purchased a new position in Compass Therapeutics in the 4th quarter valued at $26,000. BNP Paribas Financial Markets acquired a new position in Compass Therapeutics in the 4th quarter valued at $27,000. Finally, XTX Topco Ltd purchased a new position in Compass Therapeutics during the 3rd quarter worth $37,000. Institutional investors and hedge funds own 68.43% of the company's stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.